目的 统计分析2020年1月—2024年6月天津市宝坻区人民医院新型抗肿瘤药物的使用情况，分析其使用趋势，为医院新型抗肿瘤药物的科学管理和临床合理用药提供参考。方法 采用世界卫生组织推荐的限定日剂量（DDD）分析方法，计算每种新型抗肿瘤药物的用药频度（DDDs）、日均费用（DDC），并对药物的销售金额和DDDs分别进行排序，计算其排序比（B/A）。结果 2020年1月—2024年6月天津市宝坻区人民医院新型抗肿瘤药物共30个品种，其中15种小分子靶向药物15种大分子单克隆抗体类药物，销售金额和使用频率均以大分子单克隆抗体类新型抗肿瘤药物为主，占比90%以上。其中卡瑞利珠单抗使用的同步性最好，除2022年利妥昔单抗外，其余药物DDC均呈下降趋势。结论 天津市宝坻区人民医院新型抗肿瘤药物使用基本合理。

Objective To analyze the use of new antitumor drugs in Tianjin Baodi Hospital from January 2020 to June 2024, and analyze their use trend, so as to provide reference for the scientific management and clinical rational drug use of new antitumor drugs in the hospital. Methods Using the analysis method of defined daily dose (DDD) recommended by the World Health Organization (WHO), the medication frequency (DDDs) and average daily cost (DDC) of each hepatoprotective drugs were calculated, and the sales amount and DDDs of drugs were ranked, respectively, and the ranking ratio was calculated. Results From January 2020 to June 2024, Tianjin Baodi District People’s Hospital has a total of 30 types of new anti-tumor drugs, including 15 small-molecule targeted drugs and 15 large-molecule monoclonal antibody drugs. The sales sum and frequency of use are mainly large-molecule monoclonal antibody novel anti-tumor drugs, accounting for more than 90%. Among them, the use of carrilizumab had the best synchronization, and except for rituximab 2022, the DDC of other drugs showed a downward trend. Conclusion The use of new antitumor drugs in Tianjin Baodi Hospital is basically reasonable.

R979.1

国家抗肿瘤药物临床应用监测网肿瘤规范化诊疗中青年研究基金项目（DSS-YSF-2023002）